中文版 | English

在结果中检索

KIB OpenIR

浏览/检索结果: 共3条，第1-3条 帮助

已选(0)清除 条数/页：   排序方式：
Parabacteroides distasonis ameliorates hepatic fibrosis potentially via modulating intestinal bile acid metabolism and hepatocyte pyroptosis in male mice 期刊论文
NATURE COMMUNICATIONS, 2023, 卷号: 14, 期号: 1, 页码: 1829
作者:  Zhao,Qi;  Dai,Man-Yun;  Huang,Ruo-Yue;  Duan,Jing-Yi;  Zhang,Ting;  Bao,Wei-Min;  Zhang,Jing-Yi;  Gui,Shao-Qiang;  Xia,Shu-Min;  Dai,Cong-Ting;  Tang,Ying-Mei;  Gonzalez,Frank J. J.;  Li,Fei
浏览  |  Adobe PDF(5393Kb)  |  收藏  |  浏览/下载：87/15  |  提交时间：2024/05/09
FATTY LIVER-DISEASE  INDUCED CHOLESTASIS  STELLATE CELLS  PROBIOTICS  PROTECTS  INFLAMMATION  APOPTOSIS  OBESITY  AXIS  
Prebiotic-Based Nanoamorphous Atorvastatin Attenuates Nonalcoholic Fatty Liver Disease by Retrieving Gut and Liver Health 期刊论文
SMALL STRUCTURES, 2023, 页码: 2200312
作者:  Cui,Jin-Jin;  Li,Rui;  Ma,Xiao-Lei;  Yu,Hao-Yang;  Luo,Zhi-Gang;  Du,Peng;  Ren,Ling;  Ding,Xiao;  Guo,Xiu-Ping;  Zheng,Wen-Sheng;  Jiang,Jian-Dong;  Che,Yongsheng;  Wang,Lu-Lu
浏览  |  Adobe PDF(26415Kb)  |  收藏  |  浏览/下载：82/19  |  提交时间：2024/07/30
atorvastatin  gut flora  nanoamorphous  nonalcoholic fatty liver disease  prebiotics  SOLID DISPERSIONS  STATIN USE  EFFICACY  STEATOHEPATITIS  FORMULATION  SAFETY  ABSORPTION  ACTIVATION  MICROBIOTA  CIRRHOSIS  
Lipid Disorders in NAFLD and Chronic Kidney Disease 期刊论文
BIOMEDICINES, 2021, 卷号: 9, 期号: 10, 页码: 1405
作者:  Yang,Meng;  Geng,Chang-An;  Liu,Xinguang;  Guan,Min
收藏  |  浏览/下载：100/0  |  提交时间：2022/04/02
lipid  NAFLD  chronic kidney disease  NONALCOHOLIC FATTY LIVER  ENDOPLASMIC-RETICULUM STRESS  MESENCHYMAL STEM-CELLS  INSULIN-RESISTANCE  LIPOPROTEIN METABOLISM  OBETICHOLIC ACID  RENAL-FIBROSIS  RECEPTOR-ALPHA  MOUSE MODEL  ER STRESS